Markus Muenz
Amgen (Germany)(DE)
Publications by Year
Research Areas
Monoclonal and Polyclonal Antibodies Research, CAR-T cell therapy research, Immune Cell Function and Interaction, Nanoparticle-Based Drug Delivery, HIV Research and Treatment
Most-Cited Works
- → Immunotherapy combinations overcome resistance to bispecific T cell engager treatment in T cell–cold solid tumors(2021)110 cited
- → Antiviral Activity of HIV gp120-Targeting Bispecific T Cell Engager Antibody Constructs(2018)46 cited
- → Abstract 55: Generation of half-life extended anti-CD33 BiTE® antibody constructs compatible with once-weekly dosing(2017)28 cited
- → Preclinical Assessment of AMG 596, a Bispecific T-cell Engager (BiTE) Immunotherapy Targeting the Tumor-specific Antigen EGFRvIII(2021)28 cited
- → Bispecific T cell engaging antibody constructs targeting a universally conserved part of the viral M2 ectodomain cure and prevent influenza A virus infection(2017)15 cited
- → Abstract ND06: AMG 305, a dual targeting BiTE®molecule with selective activity for solid tumors that co-express CDH3 and MSLN(2023)8 cited
- → Abstract 6313: Evaluation of a dual CD123-FLT3 BiTE molecule for acute myeloid leukemia(2022)1 cited
- → Preclinical characterization of an EGFRvIII/CD3 specific BiTE® antibody construct for the treatment of glioblastoma multiforme(2016)
- Plasma cell antibody repertoire analysis following administration of meningococcal polysaccharide and protein-polysaccharide conjugate vaccines: evidence of distinct patterns of B cell activation(2014)
- → Abstract 4734: Impact of various immune escape mechanisms on redirected lysis by T cells engaged via EpCAM/CD3 bispecific BiTE® antibody AMG 110 .(2013)